FLT3 and acute myeloid leukemia: In this current manuscript, we analyze a larger cohort of older/unfit patients with newly diagnosed FLT3 mutated AML (including the 12 cases reported previously [19]) treated with a triplet regimen (low-intensity chemotherapy + FLT3 inhibitor + venetoclax) and compare the CR and CRc rates, MRD dynamics, count recovery kinetics, early mortality, and OS with patients who received a doublet regimen (low-intensity chemotherapy + FLT3 inhibitor) at our institution within the last decade.